Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

 
• By Joseph Haas, Ian Haydock, Anju Ghangurde, and Vibha Ravi
DealWatch_1200x675

More from Deals

More from Business